HCPCS Code Descriptor:
Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
70121-1755-01, 70121-1755-07, 70121-1754-01, 70121-1754-07
Route of Administration:
Potential NDC Listing Errors:
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
Alymsys is an Oncology drug manufactured by Amneal Biosciences and administered via the Intravenous route of administration. The Q Code: Q5126 is aligned to the drug Alymsys.
Alymsys is an artificial antibody (IgG1) that can be used to treat various types of cancer. This medication blocks the VEGF protein which decreases tumor growth rate. Alymys is manufactured by Amneal Biosciences and is a biosimilar to the medication Avastin (J9035). The HCPCS code for Alymsys is Q5126, this HCPCS code was aligned to the medication January 2023. It was previously aligned to the HCPCS code C9142 from October 2022 through December 2022. Patient assistance programs for Alymsys can be found through the Amneal Patient assistance program.